GlassScriptPhysician profile
William L Lawing
NPI 1144295783
$2,518.06
in general payments reported to CMS, 2019-2025
21 companies · $571 in 2025
The $571 reported for 2025 was more than what 91% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $310 · 2020: $44.77 · 2021: $283 · 2022: $606 · 2023: $412 · 2024: $293 · 2025: $571.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,275.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,275.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $488.57 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $377.37 | 2019-2024 | |
| Abbvie INC. | $323.43 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $172.84 | 2021-2023 | Jardiance |
| Janssen Pharmaceuticals, INC | $169.07 | 2020-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $150.70 | 2019-2025 | Zerbaxa, Dificid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $146.87 | 2022-2025 | Xifaxan |
| Sk Life Science, INC. | $130.67 | 2025 | |
| Novo Nordisk INC | $99.17 | 2019-2024 | Rybelsus, Ozempic |
| Alexion Pharmaceuticals, INC. | $77.78 | 2021-2025 | Ultomiris |
| Astrazeneca Pharmaceuticals LP | $74.69 | 2022-2024 | Lokelma |
| Allergan, INC. | $62.05 | 2019 | |
| Paratek Pharmaceuticals, INC. | $39.02 | 2022 | |
| Smith+Nephew, INC. | $38.75 | 2025 | Collagenase Santyl |
| E.R. Squibb & Sons, L.L.C. | $36.50 | 2021-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $29.60 | 2024 | |
| Electromed, INC. | $28.78 | 2023 | Smartvest |
| Bioxcel Therapeutics, INC. | $23.10 | 2023 | Igalmi |
| Genzyme Corporation | $19.47 | 2022 | |
| Mylan Specialty L.P. | $15.91 | 2019 | |
| Boston Scientific Corporation | $13.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Lawing listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.